Boehringer Ingelheim Vetmedica, Inc.
3902 Gene Field Road
St. Joseph, Missouri 64506
- Phone 866-638-2226
- Fax 816-326-9167
(N. butylscopolammonium bromide)
BUSCOPAN is indicated for the control of abdominal pain (colic) associated with spasmodic colic, flatulent colic, and simple impactions in horses.
BUSCOPAN is the only FDA-approved antispasmodic for use in horses. BUSCOPAN was shown to have an 88% success rate in achieving a clinical response within 30 minutes of administration.1
BUSCOPAN should not be used in impaction colics associated with ileus, or in horses with glaucoma. Not recommended for use in nursing foals or in pregnant or lactating mares, as safety has not been established. The effects may be potentiated by the concomitant use of other anticholinergic drugs. Studies of concomitant administration with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring adjunctive therapy. Administration results in heart rate elevation. Heart rate cannot be used as a valid indicator of severity of pain for 30 minutes following IV injection.
Not for use in humans. Not for horses intended for human consumption. Keep out of reach of children.
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Administer a single injection of 0.3 mg/kg body weight (0.14 mg/lb), slowly IV. This is equivalent to 30 mg N-butylscopolammonium bromide per 100 kg (220 pounds) body weight or 1.5 mL of BUSCOPAN Injectable Solution per 100 kg (220 pounds) body weight. See insert for complete dosing table.
1. FOI Summary NADA 141-228